Journal of Bioequivalence & Bioavailability

Leyte JL

Publications

• Research Article
  Alpha-D-Galactosidase does not Interfere with Trimebutine Oral Pharmacokinetics in Mexican Healthy Volunteers
  Author(s): Peñaloza-Becerra CA, Ortega-Escamilla E, Vásquez JEV, Marcelín-Jiménez G, Ángeles AP, García-González A, Leyte JL, Koretzky SG, Batista-Dieguéz D and López-Sánchez PPeñaloza-Becerra CA, Ortega-Escamilla E, Vásquez JEV, Marcelín-Jiménez G, Ángeles AP, García-González A, Leyte JL, Koretzky SG, Batista-Dieguéz D and López-Sánchez P
  
  Gas production is a common symptom in bowel affections. There are different formulations to improve general symptoms, including motility regulators, such as trimebutine, and surfactants, such as simethicone, or both. These approaches, however, do not affect gas production. Methane, hydrogen, carbon dioxide, and water are generated in the intestines due to action of bacterial flora on non-digestible carbohydrates from the diet. The unfolding of these carbohydrates by specific enzymes promises greater improvement of symptomatology. Alpha-D-Galactosidase degrades these carbohydrates from diet. It is not known whether the addition of this enzyme modifies trimebutine pharmacokinetics. Thus, our aim was to assess whether the addition of Alpha-D-Galactosidase to a commercial formulation alters trimebutine oral pharmacokinetics. We conducted a controlled, cross-ov.. View More»
  DOI: 10.4172/jbb.1000342

  Abstract PDF